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DOI 10.1186/s12885-015-1210-4RESEARCH ARTICLE Open AccessAurora kinase B is important for antiestrogen
resistant cell growth and a potential biomarker
for tamoxifen resistant breast cancer
Sarah L Larsen1, Christina W Yde1, Anne-Vibeke Laenkholm2, Birgitte B Rasmussen3, Anne Katrine Duun-Henriksen4,
Martin Bak5, Anne E Lykkesfeldt1 and Tove Kirkegaard1,6*Abstract
Background: Resistance to antiestrogen therapy is a major clinical challenge in the treatment of estrogen receptor
α (ER)-positive breast cancer. The aim of the study was to explore the growth promoting pathways of antiestrogen
resistant breast cancer cells to identify biomarkers and novel treatment targets.
Methods: Antiestrogen sensitive and resistant T47D breast cancer cell lines were used as model systems. Parental
and fulvestrant resistant cell lines were subjected to a kinase inhibitor library. Kinase inhibitors preferentially targeting
growth of fulvestrant resistant cells were identified and the growth inhibitory effect verified by dose–response cell
growth experiments. Protein expression and phosphorylation were investigated by western blot analysis. Cell cycle
phase distribution and cell death were analyzed by flow cytometry. To evaluate Aurora kinase B as a biomarker for
endocrine resistance, immunohistochemistry was performed on archival primary tumor tissue from breast cancer
patients who have received adjuvant endocrine treatment with tamoxifen.
Results: The selective Aurora kinase B inhibitor barasertib was identified to preferentially inhibit growth of fulvestrant
resistant T47D breast cancer cell lines. Compared with parental cells, phosphorylation of Aurora kinase B was higher in
the fulvestrant resistant T47D cells. Barasertib induced degradation of Aurora kinase B, caused mitotic errors, and
induced apoptotic cell death as measured by accumulation of SubG1 cells and PARP cleavage in the fulvestrant
resistant cells. Barasertib also exerted preferential growth inhibition of tamoxifen resistant T47D cell lines. Finally,
high percentage of Aurora kinase B positive tumor cells was significantly associated with reduced disease-free
and overall survival in 261 ER-positive breast cancer patients, who have received tamoxifen as first-line adjuvant
endocrine treatment.
Conclusions: Our results indicate that Aurora kinase B is a driving factor for growth of antiestrogen resistant T47D
breast cancer cell lines, and a biomarker for reduced benefit of tamoxifen treatment. Thus, inhibition of Aurora kinase B,
e.g. with the highly selective kinase inhibitor barasertib, could be a candidate new treatment for breast cancer patients
with acquired resistance to antiestrogens.
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The selective estrogen-receptor α (ER) modulator, tam-
oxifen, is the recommended first-line adjuvant endocrine
therapy for premenopausal women with ER-positive
breast cancer, whereas postmenopausal women with ER-
positive breast cancer will be offered an aromatase inhibi-
tor. Although many patients benefit from the treatment,
de novo or acquired resistance occurs in approximately
30% of the patients, and is therefore a major clinical chal-
lenge [1,2]. Following relapse, many patients will benefit
from treatment with the pure antiestrogen fulvestrant, a
selective ER down regulator, which induces degradation of
ER upon binding and subsequently abolishes ER signaling
[3,4]. However, in spite of initial response, almost all pa-
tients with advanced disease eventually develop resistance
against antiestrogen therapy [1,3,5-7].
Cell model systems are valuable tools to study the mo-
lecular mechanisms for endocrine resistant breast cancer.
We have developed in vitro cell culture models based on
the ER-positive and estrogen responsive human breast
cancer cell lines MCF-7 and T47D [8-11]. In line with
other studies, we have shown that growth of breast cancer
cell lines can switch from being ER-driven to being medi-
ated by the HER receptors upon acquisition of resistance
[12-18]. HER2 gene amplification or protein over expres-
sion in breast cancer is associated with a significantly
shorter time to relapse, poor survival and reduced sensi-
tivity to endocrine therapy [19-21]. We have previously
shown that the expression of HER2 was increased in the
T47D-derived fulvestrant resistant cell lines compared
with the parental antiestrogen sensitive T47D breast can-
cer cells. However, resistant cell growth was not preferen-
tially inhibited by knockdown of HER2 or by inhibition of
HER receptor activity [11]. These findings indicate that
HER signaling presumably does not account for all cases
of breast cancer resistance, emphasizing the need for con-
tinued investigations of the resistance mechanisms.
Tumor expansion depends on continued growth of
tumor cells through mitotic cell division. A key mitotic
regulator is the chromosomal passenger complex (CPC),
composed of the catalytic component Aurora kinase B
and the three regulatory and targeting components; inner
centromere protein (INCENP), survivin and borealin.
CPC is important for chromosome condensation, correc-
tion of erroneous kinetochore-microtubule attachments,
activation of the spindle-assembly checkpoint and cyto-
kinesis [22]. The function of Aurora kinase B is linked
to chromatin modification in relation to phosphoryl-
ation of histone H3 at Ser10 [23]. The expression of
Aurora kinase B is cell cycle regulated and the kinase
is activated upon binding to INCENP, which is both a
substrate and a positive regulator of Aurora kinase B
[24,25]. Over expression of Aurora kinase B is evident
in a range of primary cancers, such as prostate, headand neck, colon and thyroid cancers, and is associated
with clinical aggressiveness [26,27].
To explore the molecular mechanisms driving anties-
trogen resistant cell growth, we have utilized a large kin-
ase inhibitor library comprising 195 kinase inhibitors on
parental and fulvestrant resistant T47D breast cancer cell
lines. We identified Aurora kinase B as a putative novel
therapeutic target in fulvestrant and tamoxifen resistant
breast cancer cells, and further explored its role in signal-
ing and growth of fulvestrant resistant T47D cell lines by
using the selective Aurora kinase B inhibitors, barasertib
and hesperadin. Moreover, we investigated the clinical
relevance of Aurora kinase B expression in primary tu-
mors from breast cancer patients receiving tamoxifen as
first-line adjuvant endocrine therapy.
Methods
Cell lines, culture condition and reagents
The T47D cell line was originally obtained from the
Human Cell Culture Bank (Mason Research Institute,
Rockville, MD, USA) and maintained as previously de-
scribed [11]. The fulvestrant resistant cell lines; T47D/
182R-1 (182R-1) and T47D/182R-2 (182R-2) were estab-
lished from T47D grown with 5% fetal calf serum (FCS)
and long term treated with 100 nM fulvestrant (Tocris,
Avonmouth, Bristol, UK) as described in [11]. To enable
ER-mediated growth inhibition by tamoxifen, the T47D
cell line was adapted to grow in medium (RPMI, 8 μg/ml
insulin and 2 mM glutamax) supplemented with only 2%
FCS (T47D/S2). This cell line was used for establishment
of the tamoxifen resistant cell lines T47D/TR-1 (TR-1)
and T47D/TR-2 (TR-2) [28]. The fulvestrant and tamoxifen
resistant cell lines were maintained in the same growth
medium as their parental T47D cell lines plus 100 nM ful-
vestrant or 1 μM tamoxifen (Sigma-Aldrich, St. Louis, MO,
USA), respectively. For experiments, 2.5 × 105 U penicillin
and 31.25 μg/l streptomycin (Gibco, Life Technologies,
Carlsbad, CA, USA) were added to the growth medium.
Barasertib was purchased from Selleck Chemicals (Houston,
TX, USA). Stock solutions of 10−3 M fulvestrant were dis-
solved in 96% ethanol, whereas stock solutions of 10 mM
barasertib were dissolved in dimethyl sulfoxide (DMSO).
Kinase inhibitor screen
The kinase inhibitor library comprising 195 different
kinase inhibitors was purchased from Selleck Chemicals
and the experiment was performed as previously de-
scribed [28]. In brief, cells were seeded in triplicate in
96-well plates in their standard growth medium and
allowed to adhere for 2 days before 5 days treatment
with 1 μM of the kinase inhibitors. Vehicle-treated (0.1%
DMSO) controls (6–10 wells/plate) were included in
each plate. Cell viability was assayed using CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Madison,
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Flash platereader (Thermo Fisher Scientific, Waltham,
MA, USA).
Cell growth assays
Dose–response growth experiments were performed in
96-well plates. Cells were seeded in their standard
growth medium and allowed to adhere for 2 days before
5 days treatment with barasertib or JNJ-7706621 (Selleck
Chemicals) at indicated concentrations. Cell number was
determined using a crystal violet colorimetric assay as de-
scribed previously [29]. All experiments were performed at
least twice with similar results. Data represent mean values
of 6 wells ± SD from one representative experiment.
Western blot analysis
To investigate the effect of barasertib on protein expres-
sion and phosphorylation of Aurora kinase A, Aurora
kinase B and INCENP, as well as PARP cleavage, parental
and fulvestrant resistant T47D cell lines were treated for
4–96 hours with 50 nM barasertib (Selleck Chemicals).
Cell lysis and western blot analyses were performed as pre-
viously described [11]. Antibodies targeting the following
proteins were used: Aurora kinase B (1:1000, #AJ1069a,
Nordic Biosite, Copenhagen, Denmark), pThr288-Aurora
kinase A/pThr232-Aurora kinase B/pThr198-Aurora C
(1:1000, #2914, Cell Signaling Technology, Danvers, MA,
USA), INCENP (1:2000, #ab12183, Abcam, Cambridge,
MA, USA), Hsp70 (1:500,000, #MS-482-PO, Thermo
Fisher Scientific), and PARP1 (1:1400, #6639GR, BD,
Franklin Lakes, NJ, USA). All experiments were performed
using at least two independent sets of lysates with similar
results. Quantification was performed using Image J. The
protein expression level of the specific proteins was mea-
sured relative to the respective Hsp70 loading control. The
level in parental and untreated cells was set to 1.0.
Flow cytometry
For cell cycle analysis, cells were fixed in 70% ethanol
and incubated for 30 min with 20 μg/ml propidium iodide
(Sigma-Aldrich, Copenhagen, Denmark) and 40 μg/ml
RNase A (Roche, Basel, Switzerland) [30]. To detect the
fraction of phospho-Histone H3 Ser10 positive cells, cells
were fixed in 2% formaldehyde (37°C, 10 min), perme-
abilized in 90% ethanol (−20°C, overnight) and incubated
1 hour at 37°C with AlexaFluor488-conjugated phospho-
S10-Histone H3 antibody (1:50, #3465, Cell Signaling
Technology) before staining with 20 μg/ml propidium iod-
ide (Sigma-Aldrich). Cell death was measured utilizing a
SYTOX green assay, as previously described [31]. Briefly,
cells were incubated with 0.5 μmol/L SYTOX green nu-
cleic acid stain (Life Technologies) (37°C, 15 min), har-
vested in AccuMax (Thermo Fisher Scientific) and pooled
with cells from the growth medium. Samples weresubsequently resuspended in 1% FBS in PBS and kept on
ice. All samples were analyzed using FACSort flow cyt-
ometer and CellQuest Pro (BD).
Hoechst stain and fluorescence imaging
T47D, 182R-1 and 182R-2 cells were seeded in SlideFlask
Chambers and treated with 0.1% DMSO (control) or
50 nM barasertib. The cells were fixed in 4% formal-
dehyde, permeabilized by 0.2% Triton X-100, stained
with Hoechst 33342 (Life Technologies, 1:40,000) and
mounted using Fluorescence mounting medium (Dako,
Glostrup, Denmark). Pictures were captured using Zeiss
AX10 Imager A2 microscope (Carl Zeiss Microscopy,
LLC, Thornwood, NY, USA).
Patients
The cohort included 268 high-risk ER-positive postmen-
opausal breast cancer patients diagnosed between 1989
and 2001. The patients had received tamoxifen as first-
line adjuvant endocrine treatment according to the
guidelines from the Danish Breast Cancer Cooperative
Group (DBCG) [32]. The standard clinico-pathological
parameters have previously been published [33]. The
biomarker study was approved by the local ethics com-
mittee for Region South Denmark, S-VF-20040064, the
Ethical Committee waived the requirement for informed
consent from the participants.
Immunohistochemistry (IHC)
IHC was conducted on tissue microarrays (TMAs) using
a standard immunoperoxidase procedure [33]. In brief,
TMA sections, comprising two 2 mm cores from each
patient, were dewaxed and rehydrated through graded
ethanol. Antigen retrieval was performed by heat-induced
epitope retrieval (microwaving) for 15 minutes in 10 mM
Tris, 0.5 mM EDTA, pH 9. Endogenous peroxidase activ-
ity was quenched by 3% hydrogen peroxide and non-
specific binding blocked by Serum-free protein block
(Dako). Aurora kinase B antibody (1:500, #AJ1069a,
Nordic Biosite) was applied over night at 4°C. EnVision
(Dako) was used for signal amplification and positive
staining was visualized using 3.3-diaminobenzidine tetra-
hydrochloride (DAB; Dako). Nuclei were counterstained
with haematoxylin before mounting in Pertex (Histolab,
Göteborg, Sweeden). Aurora kinase B expression was
scored as percentage positive tumor cells, blindly and with-
out reference to the patient history.
Statistics
In the kinase inhibitor screen, one-tailed Student’s t-test
was performed on triplicate values comparing the growth
inhibitory effect in parental and resistant cell lines. In the
remaining experiments, group comparisons were done
using a two-tailed t-test with Bonferroni adjusted p-values
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multivariate analyses were performed. The multivariate
analysis included tumor grade, size, nodal status and age
as standard covariates. Kaplan-Meier life tables with log-
rank testing were generated to assess the association be-
tween the percentage of Aurora kinase B positive tumor
cells, and disease-free and overall survival. The statistical
analysis on the clinical data was performed in R version
3.0.1, with the R package “rms”. For all experiments, P < 0.05
were considered statistically significant.
Results
Kinase inhibitor screen identifies barasertib as a
preferential growth inhibitor of fulvestrant resistant cells
To identify kinases causally involved in fulvestrant resist-
ance, parental and fulvestrant resistant (182R-1 and
182R-2) T47D cell lines were subjected to a kinase in-
hibitor library comprising 195 inhibitors each targeting
one or more different protein kinases. The results from
the screen are shown in a volcano plot displaying, for each
of the kinase inhibitors, statistical significance (P < 0.05)
versus fold change in relative growth inhibition between
fulvestrant resistant and parental cell lines (Figure 1A).
We identified inhibitors which preferentially targeted
growth of both resistant cell lines with a statistical signifi-
cant growth inhibition which was at least two-fold higher
than the inhibition of the parental cells. The majority of
the identified kinase inhibitors which fulfilled these cri-
teria targeted the Aurora protein kinase family, whereas
no inhibitors were found to target the HER receptors
or their downstream signaling molecules Akt or ERK
(Table 1). Noteworthy, the specific Aurora kinase B in-
hibitor barasertib exerted similar growth inhibitory effect
on the fulvestrant resistant cell lines as the Aurora kinase
inhibitors targeting both Aurora kinase A and B, indicating
that Aurora kinase B is the most important Aurora kinase
in fulvestrant resistant T47D cell lines. Therefore, the
highly selective Aurora kinase B inhibitor barasertib was
explored further. Compared to untreated controls, bara-
sertib (1 μM) inhibited growth of fulvestrant resistant cell
lines by 60% whereas parental T47D cell growth was
inhibited by only 30% (Figure 1B). Another specific
Aurora kinase B inhibitor, hesperadin, also induced a pref-
erential growth inhibition of the fulvestrant resistant cell
lines in the kinase inhibitor screen, however, with a less
than two-fold growth inhibition of the resistant cells com-
pared with the parental cell line (Figure 1B).
To our knowledge, Aurora kinase B has not previously
been described to be involved in growth of antiestrogen
resistant breast cancer cells. Dose–response growth exper-
iments were conducted with increasing concentrations of
barasertib (5 nM-1.5 μM), resulting in a statistical signifi-
cant 70% growth inhibition of the resistant cells from 10
nM compared to only 30-40% growth inhibition of theparental T47D cells (Figure 1C). The results confirmed
the preferential growth inhibition of barasertib observed
in the kinase inhibitor screen (Figure 1B) and showed that
the maximal growth inhibition of parental and fulvestrant
resistant cell lines was obtained with only 10 nM baraser-
tib (Figure 1C). The morphology of parental and fulves-
trant resistant T47D cell lines upon five days treatment
with barasertib (50 nM) revealed substantial differences
between parental and resistant cell lines (Figure 1D). The
morphology of parental T47D cells was only slightly af-
fected by barasertib and the cells remained attached
to the surface. In contrast, the morphology of the ful-
vestrant resistant cells was severely changed showing
increased size of detaching apoptotic-like cells and re-
duced cell number.
Fulvestrant resistant cell lines display increased Aurora
kinase B phosphorylation, which is abolished by
barasertib
To investigate the expression and phosphorylation level
of Aurora kinase B in parental and fulvestrant resistant
T47D cell lines, western blot analysis was performed.
Comparable Aurora kinase B expression was seen in
parental and resistant cell lines, whereas phosphoryl-
ation of both Aurora kinase A and B was increased in
the fulvestrant resistant cell lines compared with the
parental T47D cells. Treatment with barasertib (50 nM)
for 4 hours resulted in undetectable level of phosphory-
lated Aurora kinase B in the resistant cells, but did not
have any effect on the level of phosphorylated Aurora kin-
ase A. Only very low levels of phosphorylated Aurora kin-
ase A and B were seen in the parental cells, and no effect
of treatment with barasertib was observed (Figure 2A).
Additionally, FACS analysis revealed that the percentage
of cells with phosphorylated mitosis-specific histone H3, a
downstream target of Aurora kinase B [34], was reduced
in both parental and fulvestrant resistant cell lines upon
treatment with barasertib (50 nM) for 24 hours (Figure 2B).
Collectively, these data support that barasertib selectively
targets Aurora kinase B.
Barasertib induces degradation of Aurora kinase B and
dephosphorylation of INCENP
To further explore the expression and function of Aurora
kinase B in T47D breast cancer cell lines, parental and re-
sistant cells were treated with barasertib (50 nM) for 4–96
hours. As seen in Figure 3, the expression of Aurora kin-
ase B was reduced to 52%, 36% and 22% in parental cells,
182R-1 and 182R-2 cells, respectively, upon 96 hours treat-
ment with barasertib. This is presumably due to degrad-
ation of Aurora kinase B as described by Gully et al. [35].
Compared with parental T47D cells, the level of the phos-
phorylated mitotic form of INCENP was increased by
1.25-fold and 2.25-fold in 182R-1 and 182R-2, respectively
Figure 1 The kinase inhibitor barasertib induces preferential growth inhibition of fulvestrant resistant cell lines. A. Parental (T47D) and
fulvestrant resistant (182R-1 and 182R-2) cell lines were treated for 5 days with a kinase inhibitor library containing 195 different kinase inhibitors
(1 μM). Cell number was assessed by a CellTiter-Glo Luminescent Cell Viability Assay. In the generated volcano plot, the box indicates kinase inhibitors
with more than two-fold greater growth inhibition of the fulvestrant resistant cells (182R-1 and 182R-2) compared to the parental T47D cells (P < 0.05).
B. Mean cell numbers of parental and resistant cells treated with barasertib (1 μM) or Hesperadin (1 μM) shown as percent of untreated control. The
results are from the kinase inhibitor screen. C. Parental and fulvestrant resistant cells treated for 5 days with the indicated concentrations of barasertib.
Cell number was determined by a crystal violet colorimetric assay and expressed as percent of untreated control. The experiments were performed
twice with six sample replicates. Representative experiments with mean ± SD are shown. D. Representative pictures of parental and resistant cells
treated for 5 days with barasertib (50 nM μM) or DMSO (control). *P < 0.05 for barasertib treated samples vs. control.
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Table 1 Inhibitors identified in the kinase inhibitor screen
Inhibitor Inhibitory Effect ± SD (%) Target(s)
T47D 182R-1 182R-2
Barasertib 28.2 ± 1.7 58.9 ± 2.2 59.9 ± 2.1 Aurora B
PHA-680632 23.5 ± 7.4 62.8 ± 2.7 56.1 ± 5.0 Aurora A/B/C
SNS-314 Mesylate 19.4 ± 1.5 47.0 ± 2.6 52.8 ± 5.1 Aurora A/B/C
ZM-447439 24.2 ± 6.1 57.7 ± 1.8 65.6 ± 1.5 Aurora A/B/C
CCT129202 20.1 ± 13.2 44.5 ± 4.8 48.8 ± 4.3 Aurora A/B/C
AMG 900 25.3 ± 3.0 55.8 ± 4.5 55.5 ± 0.6 Aurora A/B/C
JNJ-7706621 1.7 ± 5.7 27.5 ± 4.9 33.4 ± 4.8 Aurora A/B, cyclin A/CDK2, cyclin E/CDK2, cyclin B/CDK1
AT9283 6.2 ± 3.6 46.4 ± 2.5 52.6 ± 2.1 Aurora A/B, JAK2/3 and Abl
ENMD-2076 24.3 ± 16.5 61.8 ± 2.8 65.7 ± 1.5 Aurora A/B, Flt3/4, SFKs and VEGFR2
AZD7762 8.6 ± 10.3 30.3 ± 1.1 33.8 ± 2.8 Chk1/2
CX-4945 8.2 ± 2.1 27.9 ± 1.7 21.8 ± 1.7 CK2
PF-562271 1.4 ± 4.5 19.0 ± 3.5 14.8 ± 2.5 FAK and Pyk2
Nintedanib 11.8 ± 3.0 42.2 ± 3.5 33.9 ± 6.2 FGFR, VEGFR, PDGRF and SFKs
Dasatinib 18.0 ± 3.5 47.1 ± 2.7 37.0 ± 3.4 SFKs, Abl and c-Kit
TG100-115 5.0 ± 1.5 12.9 ± 2.3 13.2 ± 5.3 PI3Kγ/δ
The growth inhibitory effect of the kinase inhibitors compared with untreated cells ± standard deviation (SD). Abbreviations: Abelson (Abl), Casein kinase (CK),
checkpoint kinase (Chk), cyclin-dependent kinases (CDK), fibroblast growth factor receptor (FGFR), Fms-like Tyrosine Kinase (Flt), focal adhesion kinase (FAK), janus
kinase (JAK), platelet-derived growth factor receptor (PDGFR), proline-rich tyrosine kinase (Pyk), Src Family kinases (SFKs), vascular endothelial growth factor receptor
(VEGFR), and phosphoinositide 3-kinase (PI3K).
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phase INCENP, which moves faster through the gel than
phosphorylated INCENP [36], was similar in parental
and resistant cell lines. Treatment with barasertib (50 nM)
for 96 hours had no effect on the level of phosphory-
lated INCENP in the parental cells, but the levels were re-
duced to 49% and 42% in 182R-1 and 182R-2 cells,
respectively (Figure 3).
Barasertib induces mitotic errors and affects cell cycle
phase distribution
Aurora kinase B is important for correct cell cycle pro-
gression and plays a key role in the maintenance of normal
ploidy level during cell division [25]. To investigate whether
treatment with barasertib had an impact on chromosome
segregation and cell division, cell nuclei were stained with
Hoechst (Figure 4). Only a minor effect on chromosome
alignment in the mitotic metaphase plane was seen in par-
ental T47D cells treated with barasertib (Figure 4D). In
contrast, in the fulvestrant resistant cell lines, barasertib
had a severe effect on chromosome alignment and segre-
gation, and no dividing sister chromatids could be ob-
served (Figure 4E,F). Cell cycle analysis was therefore
performed to investigate the effect of barasertib on cell
cycle phase distribution. Parental and resistant T47D cells
were treated with barasertib (50 nM) for 24–96 hours
prior to staining with the nucleic acid dye propidium iod-
ide. Histograms presenting the cell cycle phase distribu-
tion following treatment with barasertib are shown inFigure 5A. When quantified, we found that barasertib in-
duced a shift in cell cycle phase distribution for both par-
ental and resistant cell lines (Figure 5B). Treatment with
barasertib for up to 48 hours induced accumulation of
both parental and fulvestrant resistant cells in the G2/M
phase with a concomitant decrease in the fraction of G1
cells. After 72 hours and in particular 96 hours, parental
cells with DNA content greater than 4 N was accumulat-
ing. In fulvestrant resistant cell lines, 72 and 96 hours
treatment resulted in an increase in cells with DNA con-
tent less than 2N (subG1) corresponding to dead cells
(Figure 5B).
Barasertib induces cell death of fulvestrant resistant cell
lines
The large proportion of SubG1 cells in the resistant cell
lines indicated induction of apoptosis upon treatment
with barasertib. We therefore conducted a SYTOX green
assay to further examine the effect of barasertib on cell
death in parental and fulvestrant resistant cells. In the
experiment, cisplatin was used as a positive control for
induction of cell death (Figure 6A, B). A large number
of SYTOX green-positive cells were observed in the two
fulvestrant resistant cell lines treated for 96 hours with
barasertib (50 nM) or cisplatin (20 μM) (Figure 6A, B).
SYTOX green-positive cells were quantified by flow cy-
tometry showing increased percentage of dead cells
(bold numbers) in untreated 182R-1 and 182R-2 (9.8%
and 15.9%, respectively) compared with parental T47D
Figure 2 Fulvestrant resistant cell lines exhibit increased Aurora kinase B phosphorylation, and barasertib abolishes phosphorylation
of Aurora kinase B and Histone-H3. A. Western blots showing total and phosphorylated (p) form of Aurora kinase B (Thr232) and Aurora kinase
A (Thr288) in lysates from parental (T47D) and fulvestrant resistant (182R-1 and 182R-2) cells treated with barasertib (50 nM) or DMSO (control) for
4 hours. Heat shock protein 70 (Hsp70) was used as loading control. B. Parental and resistant cells were treated with barasertib (50 nM) or DMSO
(control) for 24 hours before the cells were fixed and stained with phospho-Histone-H3 Ser10 antibody and propidium iodide prior analysis and
flow cytometry performed using a FACsort flow cytometer. M-phase phospho-Histone-H3 Ser10 positive cells are encircled and the bold numbers
indicate percentage of positive cells in each sample. Representative experiments are shown.
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Figure 3 Barasertib inhibits expression of Aurora kinase B and phosphorylation of INCENP. Western blots showing protein expression
of Aurora kinase B, INCENP and phosphorylated INCENP (p-INCENP) in lysates from parental (T47D) and fulvestrant resistant (182R-1 and 182R-2)
cells treated with barasertib (50 nM) or DMSO (control) for the indicated time periods (4–96 hours). Heat shock protein 70 (Hsp70) was used as
loading control.
Larsen et al. BMC Cancer  (2015) 15:239 Page 8 of 15cells (4.8%) (Figure 6B). Only a two-fold increase in per-
centage of dead cells to 9.6% was detected in the paren-
tal cell line upon treatment with barasertib (50 nM) for
96 hours, whereas the percentage of dead cells increased
severely to 40.1% and 53.7% for 182R-2 and 182R-2 cells,
respectively. To investigate whether the induced cell
death was caused by apoptosis, the apoptotic indicator
PARP cleavage was measured by western blot analysis.
Upon treatment for 96 hours with barasertib (50 nM),
cleaved PARP (85 kDa) was seen in the resistant cells,
whereas parental T47D cells only expressed full length
PARP (116 kDa) (Figure 6C). This indicates that cellFigure 4 Barasertib prevents chromosome alignment in fulvestrant re
D) parental, (B and E) 182R-1 and (C and F) 182R-2 T47D cells treated for 4
show higher-magnification images of dividing cells.The experiment was repdeath induced by barasertib, at least in part, was caused
by induction of apoptosis in the fulvestrant resistant
T47D breast cancer cell lines.
Aurora kinases are important for growth of tamoxifen
resistant T47D cell lines
To investigate if barasertib also inhibited growth of tamoxi-
fen resistant cell lines, dose–response growth experiments
with increasing concentrations of barasertib (5–50 nM)
were conducted on the recently established tamoxifen re-
sistant T47D breast cancer cell lines, TR-1 and TR-2 [28].
As seen in Figure 7A, treatment of the tamoxifen resistantsistant cell lines. Fluorescence microscopy of Hoechst stained (A and
2 hours with DMSO (control; A-C) or barasertib (50 nM; D-F). Inserts
eated twice and representative images are shown.
Figure 5 Barasertib causes growth arrest in the G2/M cells cycle phase. A. Parental (T47D) and fulvestrant resistant (182R-1 and 182R-1) cells
treated with barasertib (50 nM) or DMSO (control) for 24–96 hours and subsequently stained with propidium iodide. Cell cycle phase distribution
in the following phases are shown: G1 phase, S phase, G2/M phase, SubG1 and >4N (polyploid cells). B. Distribution of cells in G2/M, S, G1 and
SubG1 phases and cells with DNA content above 4N are calculated by quantification of the phase fractions seen in A. Duration of barasertib
treatment is indicated. Two individual experiments were performed and representative results are shown.
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Figure 6 Barasertib induces apoptotic cell death of fulvestrant resistant cell lines. A-B. Parental (T47D) and fulvestrant resistant (182R-1 and
182R-2) cells were treated with barasertib (50 nM), cisplatin (20 μM) or DMSO (control) for 96 hours, stained with SYTOX green and analyzed by
fluorescence microscopy and flow cytometry. Percentages of dead (SYTOX green positive) cells are indicated in bold C. Western blots showing
total and cleaved form of PARP in lysates from T47D, 182R-1 and 182R-2 cells treated with barasertib (50 nM) or DMSO (control) for 4–96 hours.
Heat shock protein 70 (Hsp70) was used as loading control. Two individual experiments were performed and data from one representative
experiment are shown.
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ential 40% growth inhibition at 10 nM barasertib com-
pared to 30% growth inhibition of the parental T47D/S2.
Thus, barasertib exerts preferential growth inhibition of
both fulvestrant and tamoxifen resistant T47D breast can-
cer cell lines. The tamoxifen resistant T47D cell lines were
less sensitive to barasertib than the fulvestrant resistant
cell lines (Figure 1C). Ectopic expression of Aurora kinase
A has recently been shown to confer resistance to tamoxi-
fen in ER-positive MCF-7 breast cancer cells through
phosphorylation of ERα [37], and as shown in Figure 7C,
the Aurora kinase A/B inhibitor JNJ-7706621 exerted
preferential growth inhibition of the ER-positive tamoxifen
resistant T47D cell lines [28] compared to the parental
T47D/S2 cells, whereas the ER-negative fulvestrant resist-
ant cell lines [11] did not display preferential growth in-
hibition to JNJ-7706621, Figure 7B.
Aurora kinase B as potential biomarker for disease-free
and overall survival of tamoxifen treated breast cancer
patients
To investigate the association between Aurora kinase B
protein expression and antiestrogen resistance, the expres-
sion of Aurora kinase B was evaluated in tumors from 261
high-risk ER-positive breast cancer patients, who had re-
ceived tamoxifen as first-line adjuvant endocrine treat-
ment. Aurora kinase B expression was confined to the
nucleus of breast cancer cells and scored as percentage
positive tumor cells (Figure 8A-D). Aurora kinase B was
expressed in 259 (97.3%) of the tumor samples, in the
range of 0-30% (Median 4%; interquartile range: 2–8.5%).
Univariate analysis revealed a statistically significant asso-
ciation between the number of Aurora kinase B positive
tumor cells and reduced disease-free and overall survival
(P = 0.0067 and P = 0.0026, respectively). In multivariate
analysis including the standard covariates; tumor grade,
tumor size, nodal status and age, Aurora kinase B was
not a significant and independent marker of decreased
disease-free or overall survival. When the tumors were
stratified into high (above median, >4%) or low (below
median, ≤4%) percentage of Aurora kinase B positive
cells, a significant association to disease-free (P = 0.0024)
and overall (P = 0.0037) survival was seen (Figure 8E,F).
Fifteen-years disease-free and overall survival for pa-
tients with high percentage of Aurora kinase B positive
tumor cells was 30% compared to 50% for patients withlow percentage of Aurora kinase B positive tumor cells
(Figure 8E,F).
Discussion
Although endocrine therapy targeting estrogen signaling
through ER has clearly improved survival of breast cancer
patients, treatment resistance is complex and a major clin-
ical challenge. To explore the molecular mechanisms be-
hind antiestrogen resistance, we have developed cell lines
resistant to the antiestrogens fulvestrant and tamoxifen
based on the estrogen responsive T47D breast cancer cell
line, and utilized a kinase inhibitor screen to identify ki-
nases involved in growth of the fulvestrant resistant T47D
cell lines. We found that the Aurora kinase B specific in-
hibitor barasertib preferentially inhibited growth of the
fulvestrant resistant T47D breast cancer cell lines com-
pared with growth of the parental fulvestrant sensitive
T47D cells. To verify the role of Aurora kinase B for ful-
vestrant resistant cell growth, siRNA-mediated knock-
down experiments were performed with several siRNA
constructs. However, we did not obtain significant knock-
down with any of the constructs, including the construct
which in our MCF-7 cells reduced Aurora kinase B ex-
pression [38]. Therefore, another Aurora kinase B specific
inhibitor hesperadin was tested and the observed prefer-
ential growth inhibition of the fulvestrant resistant cell
lines supports the role of Aurora kinase B for growth of
fulvestrant resistant T47D cells. The inhibition with
hesperadin at 1 μM was less pronounced than for 1 μM
barasertib, which may be explained by the difference in
potency of the two inhibitors, IC50 for barasertib is 0.37
nM and for hesperadin 250 nM (see www.selleckchem.
com). Aurora kinase B is a key regulator of mitosis and es-
sential for cell proliferation. It is the catalytic component
of the chromosomal passenger complex (CPC), composed
of Aurora kinase B, survivin, INCENP and borealin [22].
The complex is critical for accurate chromosomal segrega-
tion, cytokinesis, and regulation of the mitotic checkpoint
[22]. We show that phosphorylation of Aurora kinase B
and INCENP was increased in the fulvestrant resistant cell
lines compared to the level in the parental T47D cells,
indicating active CPC complex and suggesting that acti-
vation of Aurora kinase B protein is of particular import-
ance for the fulvestrant resistant T47D cell lines. Over
expression of Aurora kinase B has previously been found
to interfere with chromosome bi-orientation and the
Figure 7 Aurora kinases are important for growth of tamoxifen
resistant cell lines. Parental and tamoxifen resistant T47D cell
lines (TR-1 and TR-2) were treated for 5 days with the indicated
concentrations of barasertib (A) and parental, fulvestrant and
tamoxifen resistant T47D cell lines were treated with JNJ-7706621
(B and C). Cell number was determined by a crystal violet colorimetric
assay and expressed as percent of untreated control. The experiments
were performed twice with six sample replicates. Representative
experiments with mean ± SD are shown. *P < 0.05 for barasertib
or JNJ-7706621 treated samples vs. control.
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of kinetochore-microtubule attachments and sister chro-
matid cohesion [39]. In addition, Aurora kinase B over ex-
pression also caused abnormal cytokinesis resulting in
chromosome segregation errors [39,40]. Although we do
not find overexpression of Aurora kinase B in the fulves-
trant resistant cell lines, our finding of increased level of
the active form of Aurora kinase B and the active form of
the downstream targets INCENP and mitosis specific his-
tone H3, indicates that Aurora kinase B plays a major role
for fulvestrant resistant cell growth, and the increased cell
death, as measured by SYTOX-positive cells in the resist-
ant cell lines, compared to the untreated parental T47D
cell line, could possibly be caused by impaired cytokinesis.
In this study, barasertib preferentially inhibited fulves-
trant resistant cell growth and phosphorylation of both
Aurora kinase B and its targets INCENP and mitosis
specific histone H3 in the resistant cells. Moreover, bara-
sertib obstructed proper chromosome segregation and
induced arrest of the fulvestrant resistant cells in the
G2-phase. The increased proportion of cells in SubG1
together with PARP cleavage in the fulvestrant resistant
cell lines indicates that barasertib-induced cell death is
mediated by the apoptotic death pathway, as previously
described in a panel of human myeloma cell lines [41].
Parental T47D cells treated with barasertib also dis-
played erroneous chromosome segregation and multinu-
cleated cells. However, in contrast to the resistant cells,
progression through the cell cycle was not prevented, ra-
ther the cells reentered a new cell cycle without cytokin-
esis, resulting in polyploid cells (>4N) and cell survival,
at least for a period. Collectively, our results show that
the fulvestrant resistant cells are more vulnerable to dis-
turbance of proper cell cycle progression induced by
treatment with barasertib, and suggest that the fulves-
trant resistant cells are more dependent of Aurora kin-
ase B for survival, resulting in cell death upon inhibition
of Aurora kinase B. The primary goal of the study was
to disclose the growth promoting pathways in fulvestrant
resistant T47D cells. However; we also found significant
and preferential growth inhibition of two tamoxifen re-
sistant T47D cell lines with barasertib, but the effect was
less pronounced in the tamoxifen resistant T47D cell
lines compared to fulvestrant resistant cell lines. We
have recently shown that Aurora kinase A and ER are
major players in growth of tamoxifen resistant cell lines,
including the tamoxifen resistant T47D cell lines [28],
and Aurora kinase A has been found to confer tamoxi-
fen resistance by activating ER by phosphorylation [37].
Thus, whereas Aurora kinase B appears to play a major
role in the ER-negative fulvestrant resistant T47D cell
lines [11], Aurora kinase B may play a minor role in the
ER-positive tamoxifen resistant T47D cell lines. Major
importance of Aurora kinase A has also been found in
Figure 8 High percentage of Aurora kinase B positive tumor cells in primary breast tumors is associated with reduced recurrence-free
and overall survival. A-B. Representative pictures showing negative/low percentage (≤4% positive cells, below median) of Aurora kinase B
positive tumor cells. C-D. Representative pictures showing moderate and high percentage (>4% positive cells, above median) of Aurora
kinase B positive tumor cells. Kaplan-Meier survival curves demonstrating percentage of E) disease-free and F) overall survival of patients
with breast tumors showing low (≤4%) and high (>4%) percentage of Aurora kinase B positive tumor cells.
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Aurora kinase B also contributes to aromatase inhibitor
resistant cell growth [38]. These data support the im-
portance of Aurora kinases for growth of endocrine re-
sistant breast cancer cells and whereas Aurora kinase B
has a major role in ER-negative cells, Aurora kinase A
appears to have a major role in ER-positive breast cancer
cells.
Administration of barasertib has been shown to po-
tently inhibit growth of colon, lung, hematologic and
breast tumor xenografts as well as a panel of human
breast cancer cell lines [35,42,43]. In clinical studies, no
objective tumor response was observed in any of the pa-
tients with solid malignant tumors treated with barasertib.
However, they generally tolerated barasertib well, and 23-
25% of the barasertib-treated patients achieved prolonged
disease stabilization [44,45] (see www.clinicaltrials.gov).
Barasertib was also well tolerated in patients with acute
myeloid leukemia enrolled in clinical phase I and I/II stud-
ies. These trials showed an overall response rate of 19-25% [46,47]. Collectively, these findings suggest that breast
cancer patients resistant to antiestrogens could benefit
from treatment targeting Aurora kinase B, e.g. barasertib.
At present, we do not know the mechanisms whereby
the activity of Aurora kinase B is up regulated in our ful-
vestrant resistant cell lines or how Aurora kinase B is in-
volved in resistant cell growth. The findings in this study
suggest that the protein harbors key functions needed
for the resistant cell lines to survive upon development
of resistance. Although we do not find over expression
of Aurora kinase B in the fulvestrant resistant T47D cell
lines, over expression of Aurora kinase B may be import-
ant for tumor cell growth. Noteworthy, over expression
of Aurora kinase B in Chinese hamster embryonic diploid
fibroblasts results in aneuploidy cells capable of forming
aggressive tumors in nude mice [40] and Aurora kinase B
is found over expressed in several solid cancers, including
breast, colorectal, kidney, lung, and prostate cancer [27].
Additionally, a correlation between Aurora kinase B ex-
pression and poor survival has been demonstrated in
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squamous cell cancer and lung cancer [27,48,49]. Here,
immunohistochemical analysis performed on primary tu-
mors from ER-positive breast cancer patients, receiving
first-line adjuvant endocrine therapy with tamoxifen, re-
vealed that high percentage (above median) of Aurora kin-
ase B positive tumor cells was a marker for reduced disease-
free and overall survival in this patient cohort. Thus, Aurora
kinase B may be a marker for resistance to antiestrogens.
However, since Aurora kinase B is an important cell cycle
regulator, we cannot exclude that it is a proliferation
marker, as resistant cells may have high proliferative activ-
ity. This is to the best of our knowledge the first study
showing a link between high Aurora kinase B and reduced
benefit from tamoxifen treatment. Based on our in vitro
studies with the antiestrogen resistant T47D breast cancer
cell lines, analysis of the association between Aurora kin-
ase B and survival of breast cancer patients treated with
fulvestrant would also be of great interest. Archival breast
cancer tissue from such patients is unfortunately not avail-
able for us. Our previous findings of the importance of
Aurora kinase A and ER for growth of tamoxifen and aro-
matase inhibitor resistant breast cancer cell lines [28,38]
and for high Aurora kinase A expression as a marker for
reduced response to tamoxifen therapy [28], indicate that
both Aurora kinase A and B may be useful markers in
endocrine resistant breast cancer and also targets for
treatment.
Conclusion
In this study we found that Aurora kinase B is an import-
ant kinase for growth and signaling in the ER-negative ful-
vestrant resistant T47D breast cancer cell lines and that
Aurora kinase B also plays a role for growth of ER-positive
tamoxifen resistant T47D cell lines. Aurora kinase B was
identified as a biomarker for reduced benefit of tamoxifen
treatment. Therefore, our results indicate that Aurora kin-
ase B is a driving factor for growth of antiestrogen resist-
ant T47D breast cancer cell lines, and a biomarker for
reduced benefit of tamoxifen treatment. Thus, inhibition
of Aurora kinase B, e.g. with the highly selective kinase
inhibitor barasertib, could be a candidate new treatment
for breast cancer patients with acquired resistance to
antiestrogens.Abbreviations
Abl: Abelson; CDK: Cyclin-dependent kinases; Chk: Checkpoint kinase;
CK: Casein kinase; CPC: Chromosomal passenger complex; DAB: 3.3-
diaminobenzidine tetrahydrochloride; DBCG: Danish Breast Cancer
Cooperative Group; ER: Estrogen receptor alpha; FAK: Focal adhesion kinase,
FCS, fetal calf serum, FGFR, fibroblast growth factor receptor; Flt: Fms-like
tyrosine kinase; IHC: Immunohistochemistry; INCENP: Inner centromere
protein; JAK: Janus kinase; PDGFR: Platelet-derived growth factor receptor;
PI3K: Phosphoinositide 3-kinase; Pyk: Proline-rich tyrosine kinase;
SD: Standard deviation; SFKs: Src family kinases; TMA: Tissue micro arrays;
VEGFR: Vascular endothelial growth factor receptor.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SLL and TK were the principal investigators responsible for study design,
experimental work, interpretation of data and writing the manuscript. SLL
and CWY performed the experiments with flow cytometry, AVL, BBR and MB
were responsible for tumor collection and AVL, BBR, SLL and TK for
biomarker evaluation, AKDH performed the statistical analysis of the
biomarker study, and AEL contributed to interpretation of data and writing
of the manuscript. All authors critically read, commented and approved the
final manuscript.
Acknowledgement
We thank Birgit Reiter for excellent technical assistance and Klaus Kaae
Andersen and Anne-Sophie Soegaard for valuable help with the statistical
analysis. The study was supported by A Race Against Breast Cancer, Danish
Bank Foundation, Engineer Bent Boegh and wife Inge Boeghs Foundation
and Else and Mogens Wedel-Wedellborgs Foundation.
Author details
1Breast Cancer Group, Unit of Cell Death and Metabolism, Danish Cancer
Society Research Center, Copenhagen, Denmark. 2Department of Pathology,
Slagelse Hospital, Slagelse, Denmark. 3Department of Pathology, Herlev
Hospital, Herlev, Denmark. 4Statistics, Bioinformatics and Registry, Danish
Cancer Society Research Center, Copenhagen, Denmark. 5Department of
Clinical Pathology, Odense University Hospital, Odense, Denmark. 6Present
address: Department of Surgery, Køge Hospital, Køge, Denmark.
Received: 19 December 2014 Accepted: 18 March 2015
References
1. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer.
Annu Rev Med. 2011;62:233–47.
2. Ebctcg, Ebctcg: Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).
Effects of chemotherapy and hormonal therapy for early breast cancer on
recurrence and 15-year survival: an overview of the randomised trials.
Lancet. 2005;365:1687–717.
3. Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a
specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
Lancet. 1995;345:29–30.
4. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex):
development of a novel, “pure” antiestrogen. Cancer. 2000;89:817–25.
5. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, et al.
Fulvestrant versus anastrozole for the treatment of advanced breast
carcinoma in postmenopausal women: a prospective combined analysis of
two multicenter trials. Cancer. 2003;98:229–38.
6. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE,
McClelland RA, et al. Comparison of the effects of a pure steroidal antiestrogen
with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst.
1995;87:746–50.
7. Musgrove EA, Sutherland RL. Biological determinants of endocrine
resistance in breast cancer. Nat Rev Cancer. 2009;9:631–43.
8. Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-
regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780
sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res.
1994;54:1587–95.
9. Lykkesfeldt AE, Larsen SS, Briand P. Human breast cancer cell lines resistant
to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer.
1995;61:529–34.
10. Madsen MW, Reiter BE, Larsen SS, Briand P, Lykkesfeldt AE. Estrogen
receptor messenger RNA splice variants are not involved in antiestrogen
resistance in sublines of MCF-7 human breast cancer cells. Cancer Res.
1997;57:585–9.
11. Kirkegaard T, Hansen SK, Larsen SL, Reiter BE, Sorensen BS, Lykkesfeldt AE.
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon
acquiring resistance to the antiestrogen fulvestrant. Cancer Lett.
2014;344:90–100.
12. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV,
et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast
Larsen et al. BMC Cancer  (2015) 15:239 Page 15 of 15cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat.
2009;114:263–75.
13. Sonne-Hansen K, Norrie IC, Emdal KB, Benjaminsen RV, Frogne T,
Christiansen IJ, et al. Breast cancer cells can switch between estrogen
receptor alpha and ErbB signaling and combined treatment against both
signaling pathways postpones development of resistance. Breast Cancer Res
Treat. 2010;121:601–13.
14. Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW. Estrogen
receptor alpha is the major driving factor for growth in tamoxifen-resistant
breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat.
2013;139:71–80.
15. Pancholi S, Lykkesfeldt A, Hilmi C, Banerjee S, Leary A, Drury S, et al. ERBB2
influences the subcellular localization of the estrogen receptor in
tamoxifen-resistant MCF-7 cells leading to the activation of AKT and
p90RSK. EndocrRelat Cancer. 2008;15:985–1002.
16. Sommer A, Hoffmann J, Lichtner RB, Schneider MR, Parczyk K. Studies on
the development of resistance to the pure antiestrogen Faslodex in three
human breast cancer cell lines. J Steroid Biochem Mol Biol. 2003;85:33–47.
17. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J,
Knowlden JM, et al. Enhanced epidermal growth factor receptor signaling
in MCF7 breast cancer cells after long-term culture in the presence of the
pure antiestrogen ICI 182,780 (Faslodex). Endocrinology. 2001;142:2776–88.
18. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al.
Tamoxifen resistance in breast tumors is driven by growth factor receptor
signaling with repression of classic estrogen receptor genomic function.
Cancer Res. 2008;68:826–33.
19. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human
breast cancer: correlation of relapse and survival with amplification of the
HER-2/neu oncogene. Science. 1987;235:177–82.
20. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic
breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M,
Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive
breast cancer. N Engl J Med. 2005;353:1659–72.
22. Carmena M, Wheelock M, Funabiki H, Earnshaw WC. The chromosomal
passenger complex (CPC): from easy rider to the godfather of mitosis. Nat
Rev Mol Cell Biol. 2012;13:789–803.
23. Monier K, Mouradian S, Sullivan KF. DNA methylation promotes Aurora-B-driven
phosphorylation of histone H3 in chromosomal subdomains. J Cell Sci.
2007;120:101–14.
24. Kimura M, Uchida C, Takano Y, Kitagawa M, Okano Y. Cell cycle-dependent
regulation of the human aurora B promoter. Biochem Biophys Res Commun.
2004;316:930–6.
25. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat
Rev Mol Cell Biol. 2003;4:842–54.
26. Boss DS, Beijnen JH, Schellens JH. Clinical experience with aurora kinase
inhibitors: a review. Oncologist. 2009;14:780–93.
27. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara Jr PN, Gandara DR.
Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008;14:1639–48.
28. Thrane S, Pedersen AM, Thomsen MB, Kirkegaard T, Rasmussen BB,
Duun-Henriksen AK, Laenkholm AV, Bak M, Lykkesfeldt AE, Yde CW: A
kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel
treatment targets in antiestrogen-resistant breast cancer cells. Oncogene
2014; doi: 10.1038/onc.2014.351.
29. Lundholt BK, Briand P, Lykkesfeldt AE. Growth inhibition and growth
stimulation by estradiol of estrogen receptor transfected human breast
epithelial cell lines involve different pathways. Breast Cancer Res Treat.
2001;67:199–214.
30. Yde CW, Olsen BB, Meek D, Watanabe N, Guerra B. The regulatory
beta-subunit of protein kinase CK2 regulates cell-cycle progression at
the onset of mitosis. Oncogene. 2008;27:4986–97.
31. Yde CW, Gyrd-Hansen M, Lykkesfeldt AE, Issinger OG, Stenvang J. Breast
cancer cells with acquired antiestrogen resistance are sensitized to
cisplatin-induced cell death. Mol Cancer Ther. 2007;6:1869–76.
32. Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, et al. The
clinical database and the treatment guidelines of the Danish Breast Cancer
Cooperative Group (DBCG); its 30-years experience and future promise. Acta
Oncol. 2008;47:506–24.
33. Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.
Determination of HER2 phosphorylation at tyrosine 1221/1222 improvesprediction of poor survival for breast cancer patients with hormone
receptor-positive tumors. Breast Cancer Res. 2009;11:R11.
34. Hsu JY, Sun ZW, Li X, Reuben M, Tatchell K, Bishop DK, et al. Mitotic
phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/
PP1 phosphatase in budding yeast and nematodes. Cell. 2000;102:279–91.
35. Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, et al.
Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
Mol Cancer. 2010;9:42.
36. Goto H, Kiyono T, Tomono Y, Kawajiri A, Urano T, Furukawa K, et al.
Complex formation of Plk1 and INCENP required for metaphase-anaphase
transition. Nat Cell Biol. 2006;8:180–7.
37. Zheng XQ, Guo JP, Yang H, Kanai M, He LL, Li YY, et al. Aurora-A is a
determinant of tamoxifen sensitivity through phosphorylation of ERalpha in
breast cancer. Oncogene. 2014;33:4985–96.
38. Hole S, Pedersen AM, Lykkesfeldt AE, Yde CW. Aurora kinase A and B as
new treatment targets in aromatase inhibitor-resistant breast cancer cells.
Breast Cancer Res Treat. 2015;149:715–26.
39. Katayama H, Sen S. Aurora kinase inhibitors as anticancer molecules.
Biochim Biophys Acta. 2010;1799:829–39.
40. Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, et al. Increased
mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B
overexpression contributes to chromosome number instability. Cancer
Res. 2002;62:5168–77.
41. Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, et al. The
selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for
multiple myeloma. Br J Haematol. 2008;140:295–302.
42. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, et al.
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor
xenograft growth by inducing apoptosis. Clin Cancer Res. 2007;13:3682–8.
43. Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, et al.
AZD1152 rapidly and negatively affects the growth and survival of human
acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009;69:4150–8.
44. Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O,
et al. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B
kinase, in patients with advanced solid tumors. Invest New Drugs.
2013;31:370–80.
45. Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK,
et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in
patients with solid malignant tumors. Ann Oncol. 2011;22:431–7.
46. Tsuboi K, Yokozawa T, Sakura T, Watanabe T, Fujisawa S, Yamauchi T, et al. A
Phase I study to assess the safety, pharmacokinetics and efficacy of
barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with
advanced acute myeloid leukemia. Leuk Res. 2011;35:1384–9.
47. Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, et al.
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of
barasertib (AZD1152) in patients with advanced acute myeloid leukemia.
Blood. 2011;118:6030–6.
48. Zheng FF, Wu RC, Smith CL, O’Malley BW. Rapid estrogen-induced
phosphorylation of the SRC-3 coactivator occurs in an extranuclear
complex containing estrogen receptor. Mol Cell Biol. 2005;25:8273–84.
49. Erpolat OP, Gocun PU, Akmansu M, Karakus E, Akyol G. High expression of
nuclear survivin and Aurora B predicts poor overall survival in patients with
head and neck squamous cell cancer. Strahlen ther Onkol. 2012;188:248–54.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
